Related Experiment Videos
Cardiac effects of isoliquiritigenin
1Pharmakologisches Institut der Universität Mainz, Germany.
European Journal of Pharmacology
|May 12, 1997
Summary
Isoliquiritigenin enhances heart muscle contraction by increasing L-type Ca2+ current, likely through cyclic AMP accumulation. This suggests a potential role in managing cardiac function.
Area of Science:
- Pharmacology
- Cardiovascular Physiology
Background:
- Isoliquiritigenin is a compound with potential cardiovascular effects.
- Understanding its mechanism in cardiac muscle is crucial for therapeutic applications.
Purpose of the Study:
- To investigate the effects of isoliquiritigenin on cardiac contractility and calcium handling in rat ventricular muscle.
- To elucidate the signaling pathways involved in isoliquiritigenin's action.
Main Methods:
- Isolated rat ventricular muscle preparations were used.
- Measurements included force of contraction (Fc), L-type Ca2+ current (I(Ca)), and intracellular Ca2+ concentration ([Ca2+]i).
- Pharmacological agents like Rp-cAMPS, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, isoprenaline, forskolin, 3-isobutyl-1-methylxanthine, and milrinone were employed.
Main Results:
- Isoliquiritigenin significantly increased Fc, I(Ca), resting tension, and [Ca2+]i.
- The effects on I(Ca) were partially inhibited by Rp-cAMPS, suggesting a role for cyclic AMP.
- Isoliquiritigenin potentiated the inotropic effects of isoprenaline and forskolin, but not 3-isobutyl-1-methylxanthine.
- No further effects were observed in the presence of milrinone, indicating phosphodiesterase III inhibition.
Conclusions:
- Isoliquiritigenin exerts positive inotropic effects on rat ventricular muscle.
- The mechanism involves an increase in cyclic AMP, likely due to direct inhibition of phosphodiesterase III activity.
- These findings suggest isoliquiritigenin as a potential therapeutic agent for cardiac dysfunction.